ES3005784T3 - Treatment of cd20-positive b-cell lymphoma with obinutuzumab - Google Patents

Treatment of cd20-positive b-cell lymphoma with obinutuzumab Download PDF

Info

Publication number
ES3005784T3
ES3005784T3 ES18804720T ES18804720T ES3005784T3 ES 3005784 T3 ES3005784 T3 ES 3005784T3 ES 18804720 T ES18804720 T ES 18804720T ES 18804720 T ES18804720 T ES 18804720T ES 3005784 T3 ES3005784 T3 ES 3005784T3
Authority
ES
Spain
Prior art keywords
obinutuzumab
cycle
administration
pharmaceutical composition
hour
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18804720T
Other languages
English (en)
Spanish (es)
Inventor
Michael Wenger
Mehrdad MOBASHER
Chin-Yu Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64362606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES3005784(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES3005784T3 publication Critical patent/ES3005784T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES18804720T 2017-10-19 2018-10-19 Treatment of cd20-positive b-cell lymphoma with obinutuzumab Active ES3005784T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762574297P 2017-10-19 2017-10-19
PCT/JP2018/038924 WO2019017499A2 (en) 2017-10-19 2018-10-19 PHARMACEUTICAL COMPOSITION

Publications (1)

Publication Number Publication Date
ES3005784T3 true ES3005784T3 (en) 2025-03-17

Family

ID=64362606

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18804720T Active ES3005784T3 (en) 2017-10-19 2018-10-19 Treatment of cd20-positive b-cell lymphoma with obinutuzumab

Country Status (14)

Country Link
US (2) US12129304B2 (enExample)
EP (2) EP3697818B1 (enExample)
JP (2) JP6860652B2 (enExample)
KR (2) KR102766089B1 (enExample)
CN (2) CN120983618A (enExample)
AU (2) AU2018303836B2 (enExample)
BR (1) BR112020007731A2 (enExample)
CA (1) CA3079374A1 (enExample)
ES (1) ES3005784T3 (enExample)
IL (2) IL321935A (enExample)
MX (2) MX2020003418A (enExample)
PL (1) PL3697818T3 (enExample)
TW (2) TWI828593B (enExample)
WO (1) WO2019017499A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020003418A (es) * 2017-10-19 2020-07-20 Hoffmann La Roche Tratamiento de linfoma de células b positivo a cd20 con obinutuzumab.
US20240050562A1 (en) * 2019-10-04 2024-02-15 Chugai Seiyaku Kabushiki Kaisha Inhibitor of cell proliferation in obinutuzumab resistant cd20-positive cancer, and medicinal composition, medicine, production, method for inhibiting cell proliferation, therapeutic method, type ii anti-cd20 antibody, compounds, combination of same, enhancer and inducer, each relating thereto
JPWO2023042679A1 (enExample) 2021-09-17 2023-03-23

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME01775B (me) 2003-11-05 2011-02-28 Glycart Biotechnology Ag Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
NZ585516A (en) 2007-12-21 2012-07-27 Hoffmann La Roche Anti-cd20 antibody formulation
SI3179992T1 (sl) * 2014-08-11 2022-09-30 Acerta Pharma B.V. Terapevtske kombinacije zaviralca BTK, zaviralca PD-1 in/ali zaviralca PD-L1
US11149091B2 (en) * 2015-12-09 2021-10-19 Cedars-Sinai Medical Center Methods for treating nephrotic syndrome
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
JP6881583B2 (ja) 2017-07-21 2021-06-02 横浜ゴム株式会社 空気入りタイヤ
MX2020003418A (es) * 2017-10-19 2020-07-20 Hoffmann La Roche Tratamiento de linfoma de células b positivo a cd20 con obinutuzumab.

Also Published As

Publication number Publication date
IL321935A (en) 2025-09-01
US20200299398A1 (en) 2020-09-24
AU2018303836B2 (en) 2025-04-17
US12129304B2 (en) 2024-10-29
IL273909B2 (en) 2025-12-01
JP6860652B2 (ja) 2021-04-21
MX2024009217A (es) 2024-11-08
AU2018303836A1 (en) 2020-05-14
KR20240157135A (ko) 2024-10-31
BR112020007731A2 (pt) 2020-10-20
JP2019528282A (ja) 2019-10-10
PL3697818T3 (pl) 2025-03-24
EP3697818B1 (en) 2024-11-27
AU2025205481A1 (en) 2025-08-07
US20250026847A1 (en) 2025-01-23
TW202342099A (zh) 2023-11-01
TW201922284A (zh) 2019-06-16
IL273909B1 (en) 2025-08-01
WO2019017499A2 (en) 2019-01-24
EP4520347A3 (en) 2025-06-04
MX2020003418A (es) 2020-07-20
IL273909A (en) 2020-05-31
CA3079374A1 (en) 2019-01-24
JP2021152002A (ja) 2021-09-30
EP3697818A2 (en) 2020-08-26
WO2019017499A3 (en) 2019-02-21
CN120983618A (zh) 2025-11-21
TWI805630B (zh) 2023-06-21
CN111212854A (zh) 2020-05-29
KR102766089B1 (ko) 2025-02-13
JP7370357B2 (ja) 2023-10-27
EP4520347A2 (en) 2025-03-12
KR20200067196A (ko) 2020-06-11
TWI828593B (zh) 2024-01-01

Similar Documents

Publication Publication Date Title
US20250026847A1 (en) Treatment of cd20-positive b-cell lymphoma with obinutuzumab
BR112019015426A2 (pt) Composição farmacêutica para uso no tratamento ou prevenção de uma doença relacionada a c5 e um método para tratar ou prevenir uma doença rela-cionada a c5
TW202037604A (zh) 治療掌蹠膿疱症之抗il-36r抗體
TWI865644B (zh) 用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合
KR20200078483A (ko) 간암 치료를 위한 조성물 및 방법
KR20220091458A (ko) 비-고갈성 b 세포 억제제에 의한 면역원성을 감소시키기 위한 방법 및 조성물
CA3181827A1 (en) Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirp?-cd47 innate immune checkpoint
TW201618808A (zh) 用於長效型干擾素之劑量方案
TW202034925A (zh) Ｃｄｋ４／６抑制劑聯合免疫治療在製備治療淋巴瘤的藥物中的用途
JP2024519449A (ja) がん治療における使用のための抗ガレクチン－９抗体と化学療法剤との併用
CN117769435A (zh) 通过施用抗cd127剂治疗cd127阳性癌症的方法
EP4301409A1 (en) Methods for the treatment of gpp
US11634488B2 (en) Treatment of B cell malignancies using afucosylated pro-apoptotic anti-CD19 antibodies in combination with anti CD20 antibodies or chemotherapeutics
HK40031517A (en) Treatment of cd20-positive b-cell lymphoma with obituzumab
BR102022017167A2 (pt) Terapia anti-cd19 em combinação com lenalidomida para o tratamento de leucemia ou linfoma
US20240025987A1 (en) Use of anti-il-27 antibodies
CN119031933A (zh) 蛋白酶体抑制剂与抗pd-1抗体的药物组合
KR20220121793A (ko) 이식편대숙주 질환의 예방 또는 치료에 있어서의 화합물의 용도